SNF 472

Drug Profile

SNF 472

Alternative Names: Hexasodium phytate; SNF472

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Laboratoris Sanifit
  • Class Antineoplastics; Calcium regulators; Small molecules; Sugar alcohols
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Calciphylaxis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Calciphylaxis
  • Phase I/II Cardiovascular disorders

Most Recent Events

  • 23 Jan 2017 Sanifit initiates enrolment in the CaLIPSO trial for Calciphylaxis in USA and Spain (NCT02966028) (EudraCT2016-002834-59)
  • 20 Oct 2016 Phase-II clinical trials in Calciphylaxis in Germany (IV)
  • 20 Oct 2016 Phase-II clinical trials in Calciphylaxis in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top